Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brooke Matthews

Nurse Practitioner, Primary Care Suwanee, GA Nurse Practitioner

NPI 1093271918 CMS profile 10913713

5400 Laurel Springs Pkwy, Suwanee, GA 30024

Open in the dashboard

General payments

$3,775

192 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brooke Matthews of Suwanee, GA is reported in the CMS Open Payments database as having received $3,775 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $436 22
2024 General $740 42
2023 General $824 37
2022 General $816 40
2021 General $958 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brooke Matthews
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Brooke Matthews were reported at $436. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Brooke Matthews Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $958 $137 $39–$445 $132
2022 $816 $139 $44–$421 $149
2023 $824 $163 $53–$481 $160
2024 $740 $176 $54–$511 $164
2025 $436 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Melinta Therapeutics, Inc. $1,174 74 payments
  2. Gilead Sciences, Inc. $385 17 payments
  3. Merck Sharp & Dohme Corporation $357 18 payments
  4. La Jolla Pharmaceutical Company $330 16 payments
  5. Paratek Pharmaceuticals, Inc. $276 13 payments
  6. Astellas Pharma US Inc $205 4 payments
  7. Janssen Biotech, Inc. $199 14 payments
  8. ViiV Healthcare Company $144 7 payments
  9. AbbVie, Inc. $140 8 payments
  10. Shionogi Inc $139 5 payments
  11. Other $425 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,583 189 payments
  2. Education $191 3 payments
Products named General payments · program years 2021–2025
  1. Orbactiv $1,174 74 payments
  2. Kimyrsa $931 63 payments
  3. Vabomere $814 46 payments
  4. Rezzayo $507 40 payments
  5. XERAVA $330 16 payments
  6. NUZYRA $276 13 payments
  7. DIFICID $260 13 payments
  8. SYMTUZA $231 15 payments
  9. DELSTRIGO $197 10 payments
  10. PIFELTRO $172 9 payments
  11. Other $1,230 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record